Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 902 of 6351
-
Immune cells engineered to attack brain tumors enter human testing
Disease control Recruiting nowThis is an open label, non-randomized, single site Phase I study to test the manufacturing feasibility and safety of locoregional (LR) administration of B7-H3CART into the central nervous system of adult subjects with recurrent IDH wild-type GBM using a standard 3+3 dose escalati…
Phase 1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug shows promise against tough cancers in first chinese trial
Disease control OngoingResearchers are looking for a better way to treat advanced Triple-Negative Breast Cancer (TNBC) and Non-Small-Cell Lung Cancer (NSCLC). "Advanced" usually means that the cancer keeps growing even with treatment. The cancer may also be "metastatic", which means that it has spread …
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can cash incentives and a quit-smoking pill curb both drinking and smoking?
Disease control Recruiting nowUsing a randomized controlled trial (RCT), the goal of this study is to evaluate the ability of evidence based behavioral treatment (contingency management: CM) to significantly decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorde…
Phase 2 • Sponsor: Washington State University • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Can a 16-Hour fast supercharge heart rehab?
Disease control CompletedThis study will use a form of intermittent fasting called time-restricted eating (TRE) where individuals consume ad libitum energy intake within a set window of time, commonly 8 hours, which induces a fasting window of 16 hours per day (i.e., 16:8 TRE). TRE could be an effective …
Sponsor: University of Toronto • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Blood pressure trial aims to keep Seniors' minds sharp
Prevention Recruiting nowThe PCOT study is a multi-site randomized trial of patients 70 years or older with high BP. The main goal of the study Preventing Cognitive Decline by Reducing BP Target Trial (PCOT) is to conduct a large pragmatic clinical trial (PCT) to test the hypothesis that patients who rec…
Sponsor: University of Texas Southwestern Medical Center • Aim: Prevention
Last updated Jun 27, 2026 08:01 UTC
-
Needles vs. nerve pain: can acupuncture shield breast cancer patients from chemotherapy side effects?
Symptom relief OngoingSome people experience a side effect while they are receiving taxane called taxane-induced peripheral neuropathy (TIPN). TIPN is pain in the arms and legs due to nerve damage caused by cancer treatment and may interfere with quality of life. The purpose of this study is to learn …
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
New drug aims to heal hearts after attack – trial results awaited
Disease control CompletedThis is a Phase 2, multicenter, randomized, parallel, 3-arm, placebo-controlled study to assess efficacy and safety of CDR132L in patients with reduced Left Ventricular Ejection Fraction (LVEF) (≤ 45%) after myocardial infarction (MI). This study consists of a screening period (t…
Phase 2 • Sponsor: Cardior Pharmaceuticals GmbH • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
First mRNA vaccine against deadly nipah virus shows promise in early trial
Vaccine CompletedBackground: Nipah virus (NiV) is transmitted from animals to humans, from humans to humans, and through contaminated food. Infected people may have a cough and trouble breathing. Some people may develop serious symptoms, such as brain infection and inflammation, that can lead to…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Jun 27, 2026 07:55 UTC
-
New hope for rare blood cancer: drug combo targets hard-to-treat lymphoma
Disease control Recruiting nowIt is an open-label, multicenter, phase II, single arm trial to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients about 28 patients with Relapsed or Refractory Plasmablastic lymphoma.
Phase 2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Sep 09, 2026 16:00 UTC
-
One pill could change the fight against sleeping sickness in kids
Disease control CompletedAcoziborole has been studied in an open-label pivotal Phase II/III trial (DNDi-OXA-02-HAT) in the DRC and Guinea. As the numbers of reported cases diminish, resources for surveillance and specialised screening will also taper. This decrease, coupled with the loss of diagnostic sk…
Phase 2/3 • Sponsor: Drugs for Neglected Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can a Twice-Yearly shot stop artery plaque from growing?
Disease control OngoingCKJX839D12303 is a research study to determine if the study treatment, called inclisiran, in comparison to placebo taken in addition to statin medication can effectively reduce the total amount of plaque formed in the heart's vessels as measured by coronary computed tomography an…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New combo aims to supercharge prostate cancer radiation
Disease control Recruiting nowThis phase I/II trial tests the safety, side effects, and best dose of abemaciclib and whether it works before 177Lu-PSMA-617 in treating patients with castration resistant prostate cancer that has spread to other places in the body (metastatic). Abemaciclib is in a class of medi…
Phase 1/2 • Sponsor: Vadim S Koshkin • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Blood test may guide chemo choices for colon cancer patients
Disease control Recruiting nowThis Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Phase 2/3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New antibody cocktail shields vulnerable patients from COVID-19
Prevention CompletedA weak immune response to two doses of vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been observed in immunocompromised patients, including solid organ transplant recipients (SOTRs)1,2,3. Studies focused on third dose in SOTRs revealed that the …
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Prevention
Last updated Jun 27, 2026 11:01 UTC
-
New drug combo aims to shrink rectal tumors before surgery
Disease control Stopped earlyThis clinical trial is designed to determine the maximum tolerated dose of niraparib when combined with dostarlimab and hypofractionated radiation for locally advanced rectal cancer. Once this is determined, this dose will be tested to identify what impact it has on the tumor as …
Phase 1 • Sponsor: University of Iowa • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Aggressive cholesterol drugs may shrink artery plaque in young patients
Disease control Recruiting nowThis study evaluates whether plaques in young patients with familial hypercholesterolemia (aged below 50 years) are susceptible to significant plaque regression with early, intensive lipid lowering therapy.
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Bladder cancer drug combo shows promise in patients who Can't have chemo
Disease control CompletedThe purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Can a new immunotherapy combo outsmart advanced lung cancer?
Disease control CompletedThe current standard of care for locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiation and consolidation immunotherapy. In real world clinical practice, patients who cannot tolerate concurrent chemoradiation generally received radiotherapy alone or sequ…
Phase 2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill shows promise for sickle cell sufferers
Disease control CompletedThis study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease. NDec is a combination of two medicines (decitabine-tetrahydrouridine). Both medicines are new for the treatment of sickle cell disease. Participants who a…
Phase 2 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingPembrolizumab monotherapy and platinum-based chemotherapy in the combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have been widely used in daily clinical practice based on the KEYNOTE-048 study. On the other hand, doceta…
Phase 2 • Sponsor: Hokkaido University Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:28 UTC